johannes-ludwig-8dejZGw3Hec-unsplash.jpg

AOA Press Release

AOA Dx Co-Founders Oriana Papin-Zoghbi and Anna Jeter Named to Inc.’s 2022 Female Founders 100 List

September 27, 2022

AOA Dx  is proud to announce that  co-founders Oriana Papin-Zoghbi and Anna Jeter have been named to Inc.’s 2022 Female Founders 100 List.

Inc.’s fifth annual Female Founders 100 list honors a bold group of 100 women whose innovations and ideas are shaping the world into a better place. Collectively, the 2022 honorees’ companies are estimated to be worth more than $22 billion.

 

Each year, Inc. editors review thousands of applications highlighting female founders who are challenging the status quo and tackling some of the world’s biggest problems. The list features women who have overcome challenges and lifted those around them, while leading impactful organizations across the country.

The founders cross all industries and bring with them unique stories of success from each stage of the entrepreneurial journey — from startup to going public, being acquired by big buyers, or spending decades at the helm of an organization. They are reinventing everything from shoes to food and are challenging issues like financial literacy and reproductive health.

“These 100 female founders have identified solutions to difficult problems and created valuable, industry-changing companies out of them. We congratulate this year’s list on their achievements and look forward to their continued success,” says Inc. editor-in-chief Scott Omelianuk.

 

Under Papin-Zoghbi and Jeter’s leadership, AOA Dx has made significant headway in developing the first early detection tool for ovarian cancer. In a landmark reviewed study, AOA's technology AKRIVIS GD™ showed over 90% accuracy for detection of ovarian cancer, including early stage disease when 5 year survival rates are greater than 90%.

AKRIVIS GD™, a liquid biopsy assay for early detection of ovarian cancer, has shown high sensitivity and specificity, addressing an urgent market need. These results were verified and published in the Journal of Precision Medicine.

 

“We are extremely honored to receive this recognition by  Inc. and to be among a group of such talented and innovative women.  We are working so hard every single day to help give women the tools they deserve to better their health. We thank Inc. for recognizing our passion for what we do and the impact we strive to make in women’s health.”  said Oriana Papin Zoghbi, CEO and Co-Founder of AOA Dx and Anna Jeter, Chief Development OFficer and Co-Founder of AOA Dx. 

Inc. magazine’s Female Founders 100 issue (October 2022) will be available online at https://www.inc.com/magazine and on newsstands on October 4.

 

About Inc.

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning, multiplatform content reaches more than 50 million people each month across a variety of channels, including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States.

The global recognition that comes with inclusion among the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc.

For more information, visit www.inc.com.

About AOA Dx Inc

 

AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. 

 

More information can be found at www.aoadx.com.

 

Contact

Corporate Communications